PIONEERING TREATMENTS FOCUSED ON COUNTERACTING HEART DYSFUNCTION
Cytokinetics is developing CK-136, an investigational, novel, selective, oral, small molecule cardiac troponin activator, as a potential treatment of patients with heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility.
In preclinical models, CK-136 increased myocardial contractility by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium, facilitating more actin-myosin cross bridge formation during each cardiac cycle thereby resulting in increased myocardial contractility. Similar to cardiac myosin activation, preclinical research has shown that cardiac troponin activation does not change the calcium transient of cardiac myocytes.
CK-136 is the subject of a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study assessing the safety, tolerability and pharmacokinetics of CK-136 when administered orally as single or multiple doses to healthy participants.